Dads Who Go Beyond
The Scores are Falling! The IQ Scores are Falling!

New Pentavalent Rotavirus Vaccine Shows Little Efficacy Against Diarrhea

Rotovirus Dr. P
Letter to the Editor
New pentavalent rotavirus vaccine shows little efficacy against diarrhea
Lalit Kumar
drlalitnarwat@gmail.com
Jacob Puliyel
Department of Pediatrics, St Stephens Hospital, Delhi 110054, India
⁎Corresponding author.

Keywords: Rotarix; Bovine human-reassortant pentavalent vaccine; Serum Institute of India

Rotavirus vaccine is recommended as a means of reducing diarrheal morbidity and deaths in developing countries [1]. The original efficacy studies with the presently licensed vaccines were done in the USA and Europe. Efficacy against severe rotavirus infection was around 90% (95% confidence interval (CI) : 85.·1‒–94.·1) and against all-cause severe gastroenteritis it was about 50% (CI: 39.·8‒–57.·8) [2]. Efficacy was less in Africa and Asia. In Africa it was 61% (CI: 44.0‒0–73.2) 2) against severe rotavirus diarrhoea and 30% (CI: 15.0‒–42.6) against all-cause severe diarrhoea [3].
The journal Vaccine has now published the results of a Phase-III randomized-control-trial, of a newly developed pentavalent rotavirus vaccine (BRV-PV). Vaccine efficacy against rotavirus diarrhoea ,(39.5% efficacy against severe rotavirus gastroenteritis (SRVGE) in the per protocol analysis) is emphasized in the report. However, the incidence of ‘all-cause severe gastroenteritis’ was not reduced by vaccination – vaccine efficacy was reported as 4.6% (95% CI: -−5.1‒ to 13.4) [4].

From the standpoint of the scientific record, additionally highlighting the clinically relevant aspect of their findings - namely efficacy against all-cause diarrheal morbidity, would enable decision makers to make choices about the vaccine, considering costs and benefits.

The same vaccine was studied in Niger. An efficacy of 66.7% against severe rotavirus gastroenteritis was reported in the per protocol population [5]. However severe gastroenteritis due to any etiology was not significantly lower among the vaccinated (difference in rate 1.97 cases per 100 person years confidence interval [CI](CI: –- 1.,28 to –5.22) [6]. The authors did post-hoc analysis of efficacy against ‘very severe diarrhoea’ (which they defined as Vesikari score of 15 or more) and reported a difference in rate of 3.08 per 100 person years (CI: 1.79 to –4.36) among the vaccinated. As efficacy against ‘very severe diarrhea’ has not been studied previously, comparable data for other rotavirus vaccines is not available.

References

[1] Rotavirus vaccines. WHO position paper -January 2013. Wkly Epidemiol Rec 2013;88(5):49–64.
[2] T. Vesikari, A. Karvonen, R. Prymula, V. Schuster, J.C. Tejedor, R. Cohen, et al., Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind T controlled study, Lancet 370, 2007, 1757–1763.
[3] S.A. Madhi, N.A. Cunliffe, D. Steele, D. Witte, M. Kirsten, C. Louw, et al., Effect of human rotavirus vaccine on severe diarrhea in African infants, N Engl J Med 362 (4), 2010 Jan 28, 289–298.
[4] P.S. Kulkarni, S. Desai, T. Tewari, A. Kawade, N. Goyal, B.S. Garg, et al., Flores J; SII BRV-PV author group. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortantpentavalent rotavirus vaccine in Indian infants, Vaccine 35, 2017, 6228–6237.
[5] S. Isanaka, O. Guindo, C. Langendorf, A. Matar Seck, B.D. Plikaytis, N. Sayinzoga-Makombe, et al., Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger, N Engl J Med 376, 2017, 1121–1130.
[6] J. Kaur and J. Puliyel, Heat-stable oral rotavirus vaccine, N Engl J M

Comments

Shelley Tzorfas

Vaccination or Water, vaccination or Water..Researchers are having difficulty collating the results as to which is better for Diarrhea? The pharmaceutical industry does not have a clear answer and feels that more research is necessary. Universities are being given a total overall grant of one billion dollars to come up with the "Correct Scientific Results." Analysts say that this New and Improved Research should take about 10 years to complete and appear in medical journals. Since the LATIMES was just purchased by an MD Vaccine maker-"Physician entrepreneur Dr. Patrick Soon-Shiong is planning an initial public offering later this year for the company, Nant, which is developing a cancer vaccine., " the results of this study may appear in the LATIMES in less than the anticipated 10 year time-frame!

Angus Files

it was a money maker for Offit so what are we complaining about..apart from him not having the vaccine and enduring some intestinal telescoping /intussusception.

Pharma For Prison

MMR RIP

Grace Green

I thought a long time ago, rehydration kits were recommended as a means of reducing diarrheal morbidity and mortality in all countries. Surely less costly, and less risky as well.

bob moffit

Not surprised to read of questions being raised regarding "efficiency" of the vaccine .. but .. I hope some day soon to read of legitimate concerns regarding "safety" of those vaccinated who suffered severe adverse reactions following vaccination?

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name and email address are required. Email address will not be displayed with the comment.)